Titan Pharma Inc (TTNP) 0.7239 $TTNP
Titan Pharmaceuticals Presents Nonclinical Data Supporting Use of ProNeura Drug Delivery Platform in Parkinson's Disease
Marketwired - Wed Jun 17, 11:32AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today presented nonclinical data at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego demonstrating the potential of Titan's ProNeura(TM) long-term, continuous drug delivery platform in the treatment of Parkinson's disease. ProNeura-based subdermal implants containing the dopamine agonist ropinirole were first characterized for pharmacokinetics of drug release in rats followed by an evaluation of motor function and onset of treatment-related dyskinesias in an implant dose-escalating study in the Parkinsonian monkey model.
Titan Pharmaceuticals' Positive Phase III Trial Creates Clear Path To Approval
Alexander Maxwell - at Seeking Alpha - Wed Jun 17, 11:22AM CDT
Titan Pharmaceuticals to Present at the BIO International Convention
Marketwired - Wed Jun 10, 2:04PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that President Sunil Bhonsle will present at the BIO International Convention 2015 being held June 16-18 at the Pennsylvania Convention Center in Philadelphia. The presentation will take place on Tuesday, June 16 at 4:15 p.m. in Theater 3.
Stock to Watch: Titan Pharmaceuticals Up 12.3% (TTNP)
Comtex SmarTrend(R) - Mon Jun 08, 10:18AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 12.3% to $0.90 on 6.4x average daily volume. Titan Pharmaceuticals has traded 2.3 million shares thus far today, vs. average volume of 365,000 shares per day. The stock has outperformed the Dow (12.3% to the Dow's -0.2%) and outperformed the S&P 500 (12.3% to the S&P's -0.2%) during today's trading.
Titan Pharma's Probuphine subdermal implant successful in Phase 3 study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 6:53AM CDT
Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle
at The Street - Mon Jun 08, 6:01AM CDT
Titan and its partner will resubmit Probuphine for FDA approval later this year.
Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Mon Jun 08, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today reported positive topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. This study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints. It was conducted by Titan's commercialization and development partner Braeburn Pharmaceuticals and developed in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study.
Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction
PR Newswire - Mon Jun 08, 6:00AM CDT
Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine®, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. The study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints, which were established in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study. Braeburn has exclusive commercialization rights to Probuphine in the United States and Canada under a license from Titan Pharmaceuticals, Inc. (OTCQB: TTNP).
Titan Pharma schedules conference call for Monday am to discuss Probuphine Phase 3 results
Seeking Alpha - at Seeking Alpha - Fri Jun 05, 4:58PM CDT
Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Fri Jun 05, 3:36PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) announced today that it expects to report topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction, before the market opens on Monday, June 8, 2015.
Penny Stocks Research for Valmie Resources, EKSO BIONICS, NuGene, Titan Pharmaceuticals, Medican, and Auri
PR Newswire - Fri May 29, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), EKSO BIONICS (OTCBB:EKSO), NuGene (OTCBB:NUGN), Titan Pharmaceuticals (OTCMKTS:TTNP), Medican (OTCMKTS:MDCN), and Auri (OTCMKTS:AURI).
Traders Get Bullish on Shares of Titan Pharmaceuticals, Shares Up 5.7% (TTNP)
Comtex SmarTrend(R) - Thu May 21, 10:45AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.7% to $0.82 on 1.2x average daily volume. Thus far today, Titan Pharmaceuticals has traded 298,000 shares, vs. average volume of 242,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.3%) during today's trading.
Titan Prepares For Big Summer 2015
Jason Napodano, CFA - at Seeking Alpha - Sat May 16, 7:25AM CDT
Titan Pharmaceutical's (TTNP) Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 4:01PM CDT
Titan Pharmaceuticals Reports First Quarter 2015 Financial Results
Marketwired - Wed May 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the first quarter ended March 31, 2015.
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2015 Financial Results
Marketwired - Fri May 08, 1:04PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 1 p.m. EDT / 10 a.m. PDT on Thursday, May 14, 2015 to discuss the company's financial results as of March 31, 2015. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance; and Marc Rubin, M.D., executive chairman. Highlights of the first quarter and financial results will be included in a press release to be issued prior to the call.
Buy Titan Ahead Of Summer Catalyst
Alexander Maxwell - at Seeking Alpha - Fri May 08, 10:13AM CDT
TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach of Fiduciary Duty
Business Wire - Wed Apr 08, 7:21AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals, Inc. (OTC:TTNP) ("Titan Pharmaceuticals" or the "Company"
.
Titan Pharmaceuticals' (TTNP) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 2:58PM CDT
Stock to Watch: Titan Pharmaceuticals Up 5.2% (TTNP)
Comtex SmarTrend(R) - Tue Mar 31, 10:17AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.2% to $0.71 on 1.1x average daily volume. Thus far today, Titan Pharmaceuticals has traded 488,000 shares, vs. average volume of 432,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.3%) and outperformed the S&P 500 (5.2% to the S&P's -0.2%) during today's trading.
Titan Pharmaceuticals Presents Nonclinical Data Supporting Use of ProNeura Drug Delivery Platform in Parkinson's Disease
Marketwired - Wed Jun 17, 11:32AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today presented nonclinical data at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego demonstrating the potential of Titan's ProNeura(TM) long-term, continuous drug delivery platform in the treatment of Parkinson's disease. ProNeura-based subdermal implants containing the dopamine agonist ropinirole were first characterized for pharmacokinetics of drug release in rats followed by an evaluation of motor function and onset of treatment-related dyskinesias in an implant dose-escalating study in the Parkinsonian monkey model.
Titan Pharmaceuticals' Positive Phase III Trial Creates Clear Path To Approval
Alexander Maxwell - at Seeking Alpha - Wed Jun 17, 11:22AM CDT
Titan Pharmaceuticals to Present at the BIO International Convention
Marketwired - Wed Jun 10, 2:04PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that President Sunil Bhonsle will present at the BIO International Convention 2015 being held June 16-18 at the Pennsylvania Convention Center in Philadelphia. The presentation will take place on Tuesday, June 16 at 4:15 p.m. in Theater 3.
Stock to Watch: Titan Pharmaceuticals Up 12.3% (TTNP)
Comtex SmarTrend(R) - Mon Jun 08, 10:18AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 12.3% to $0.90 on 6.4x average daily volume. Titan Pharmaceuticals has traded 2.3 million shares thus far today, vs. average volume of 365,000 shares per day. The stock has outperformed the Dow (12.3% to the Dow's -0.2%) and outperformed the S&P 500 (12.3% to the S&P's -0.2%) during today's trading.
Titan Pharma's Probuphine subdermal implant successful in Phase 3 study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 6:53AM CDT
Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle
at The Street - Mon Jun 08, 6:01AM CDT
Titan and its partner will resubmit Probuphine for FDA approval later this year.
Titan Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Mon Jun 08, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) today reported positive topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. This study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints. It was conducted by Titan's commercialization and development partner Braeburn Pharmaceuticals and developed in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study.
Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction
PR Newswire - Mon Jun 08, 6:00AM CDT
Braeburn Pharmaceuticals, an Apple Tree Partners company, today reported positive topline results from the Phase 3 double-blind, double-dummy clinical study of Probuphine®, the investigational subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction. The study met the pre-specified primary endpoint of non-inferiority, as well as all secondary efficacy endpoints, which were established in consultation with the U.S. Food and Drug Administration (FDA) prior to initiating the study. Braeburn has exclusive commercialization rights to Probuphine in the United States and Canada under a license from Titan Pharmaceuticals, Inc. (OTCQB: TTNP).
Titan Pharma schedules conference call for Monday am to discuss Probuphine Phase 3 results
Seeking Alpha - at Seeking Alpha - Fri Jun 05, 4:58PM CDT
Titan Pharmaceuticals Schedules Conference Call to Review Results From Phase 3 Study of Probuphine for Opioid Addiction
Marketwired - Fri Jun 05, 3:36PM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP) announced today that it expects to report topline results from the Phase 3 double blind, double dummy clinical study of Probuphine(R), the company's subdermal implant containing buprenorphine HCl for the long-term maintenance treatment of opioid addiction, before the market opens on Monday, June 8, 2015.
Penny Stocks Research for Valmie Resources, EKSO BIONICS, NuGene, Titan Pharmaceuticals, Medican, and Auri
PR Newswire - Fri May 29, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), EKSO BIONICS (OTCBB:EKSO), NuGene (OTCBB:NUGN), Titan Pharmaceuticals (OTCMKTS:TTNP), Medican (OTCMKTS:MDCN), and Auri (OTCMKTS:AURI).
Traders Get Bullish on Shares of Titan Pharmaceuticals, Shares Up 5.7% (TTNP)
Comtex SmarTrend(R) - Thu May 21, 10:45AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.7% to $0.82 on 1.2x average daily volume. Thus far today, Titan Pharmaceuticals has traded 298,000 shares, vs. average volume of 242,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.1%) and outperformed the S&P 500 (5.7% to the S&P's 0.3%) during today's trading.
Titan Prepares For Big Summer 2015
Jason Napodano, CFA - at Seeking Alpha - Sat May 16, 7:25AM CDT
Titan Pharmaceutical's (TTNP) Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 4:01PM CDT
Titan Pharmaceuticals Reports First Quarter 2015 Financial Results
Marketwired - Wed May 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCQB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the first quarter ended March 31, 2015.
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2015 Financial Results
Marketwired - Fri May 08, 1:04PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 1 p.m. EDT / 10 a.m. PDT on Thursday, May 14, 2015 to discuss the company's financial results as of March 31, 2015. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance; and Marc Rubin, M.D., executive chairman. Highlights of the first quarter and financial results will be included in a press release to be issued prior to the call.
Buy Titan Ahead Of Summer Catalyst
Alexander Maxwell - at Seeking Alpha - Fri May 08, 10:13AM CDT
TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach of Fiduciary Duty
Business Wire - Wed Apr 08, 7:21AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals, Inc. (OTC:TTNP) ("Titan Pharmaceuticals" or the "Company"
. Titan Pharmaceuticals' (TTNP) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 01, 2:58PM CDT
Stock to Watch: Titan Pharmaceuticals Up 5.2% (TTNP)
Comtex SmarTrend(R) - Tue Mar 31, 10:17AM CDT
Titan Pharmaceuticals (NASDAQ:TTNP) is one of today's best performing penny stocks, up 5.2% to $0.71 on 1.1x average daily volume. Thus far today, Titan Pharmaceuticals has traded 488,000 shares, vs. average volume of 432,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.3%) and outperformed the S&P 500 (5.2% to the S&P's -0.2%) during today's trading.
